Menu
Search
|

Menu

Close
X

Organovo Holdings Inc ONVO.OQ (NASDAQ Stock Exchange Global Market)

1.34 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 1.34
Open --
Volume --
3m Avg Volume 199,928
Today’s High --
Today’s Low --
52 Week High 2.65
52 Week Low 0.91
Shares Outstanding (mil) 105.63
Market Capitalization (mil) 215.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
4
FY16
1
FY15
1
EPS (USD)
FY18
-0.325
FY17
-0.393
FY16
-0.422
FY15
-0.378
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
49.78
5.73
Price to Book (MRQ)
vs sector
3.77
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-69.96
14.61
Return on Equity (TTM)
vs sector
-70.97
16.34

EXECUTIVE LEADERSHIP

Taylor Crouch
President, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Sharon Presnell
Chief Scientific Officer, Since 2016
Salary: $349,462.00
Bonus: --
Jennifer Bush
Compliance Officer, General Counsel, Corporate Secretary, Since 2014
Salary: $323,115.00
Bonus: $20,000.00
Paul Gallant
General Manager, Since 2015
Salary: --
Bonus: --
Richard Maroun
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6275 Nancy Ridge Drive Suite 110
SAN DIEGO   CA   92121

Phone: +1858.5509994

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

SPONSORED STORIES